TransMedics Group Inc vs Sprott Uranium Miners ETF — how do they compare? TransMedics Group Inc trades at $87.02 (market cap $3.10B), while Sprott Uranium Miners ETF trades at $55.5. Which is the better fit depends on your goals.
| TMDX | URNM | |
|---|---|---|
Market Cap | $3.10B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $150.42 | $83.99 |
52-Week Low | $61.99 | $44.14 |
Enterprise Value | $3.49B | — |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
URNM trades at $55.39, up 1.45% today, with a bullish technical signal supported by moving averages. Recent news highlights nuclear energy's role in meeting AI power demand, with government funding and international deals creating positive momentum. The ETF focuses on uranium miners, offering concentrated exposure to the nuclear supply chain.
The outlook for URNM is positive due to growing nuclear energy demand from AI data centers and government support, though risks include uranium price volatility and concentrated miner exposure. Wall Street sentiment is mixed, with some analysts favoring pure-miner funds while others caution on valuation gaps versus spot prices.
Trailing returns across standard periods
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →